Non-Small Cell Lung Cancer
Advertisement
Learn how sublobar resection showed "comparable oncologic outcomes and complication rates" as lobectomy per a recent review.
The FDA action date for its regulatory decision is anticipated during the third quarter of this year.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
Sunvozertinib is an irreversible EGFR inhibitor that targets a wide spectrum of EGFR mutations.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
For patients with NSCLC and EGFR mutations, amivantamab plus carboplatin-pemetrexed shows OS benefits versus chemo alone.
The improvement in median OS with the combination treatment is “expected to exceed one year," officials said.
The study showed there was “preliminary evidence of central nervous system-anti-tumor activity” in some patients.
The therapy is now the “first and only subcutaneously administered PD-1 inhibitor," officials said in an announcement.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
Home-based exercise programs after lung cancer resection do not improve physical function in patients with NSCLC.
Study Highlights Importance of Pretreatment Frailty Assessments for Older Adults With Advanced NSCLC
Implementing pretreatment frailty assessments into clinical workflows may help identify patients at risk of poor outcomes.
A new study illustrated the importance of exercise for patients with lung cancer who experience cancer-related fatigue.
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
This follows the FDA’s August 2024 move to grant Priority Review for the subcutaneous amivantamab BLA.
A qualitative study of patients with NSCLC is providing insights into their experiences and perceptions.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.